Argus analyst Jasper Hellweg raised the firm’s price target on Sanofi to $60 from $55 and keeps a Buy rating on the shares. Argus likes Sanofi’s diverse range of businesses, which include branded pharmaceuticals, generics, vaccines, and consumer healthcare products, and Sanofi has a strong new drug pipeline of 84 molecular entities and vaccine candidates, of which 28 are in Phase 3 trials or have been submitted for regulatory approval, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNY:
- Sanofi upgraded to Overweight from Equal Weight at Barclays
- Sanofi Gains after Dupxient Shows Promise in COPD
- Regeneron, Sanofi report Dupixent trial meets primary and secondary endpoints
- Regeneron, Sanofi announce EC approval of Dupixent
- Regeneron, Sanofi present results from Dupixent clinical trial